Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Marina Konopleva et al.|New England Journal of Medicine|2019Cited by 502
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Naval Daver et al.|Nature Medicine|2023Cited by 372
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i> -Mutated Myeloid MalignanciesCurtis A. Lachowiez, Courtney D. DiNardo, Sanam Loghavi et al.|Blood Cancer Discovery|2023Cited by 122
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Robyn M. Scherber, Mariana Castells et al.|NEJM Evidence|2023Cited by 74